SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw unusually large options trading on Friday. Traders bought 149,934 call options on the company. This is an increase of approximately 829% compared to the average volume of 16,138 call options.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, SELLAS Life Sciences Group has an average rating of “Hold” and a consensus price target of $7.00.

Insider Activity at SELLAS Life Sciences Group

In other SELLAS Life Sciences Group news, Director Katherine Bach Kalin bought 63,400 shares of the firm’s stock in a transaction dated Wednesday, November 19th. The shares were bought at an average price of $1.59 per share, for a total transaction of $100,806.00. Following the completion of the acquisition, the director owned 104,400 shares of the company’s stock, valued at approximately $165,996. This trade represents a 154.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.40% of the company’s stock.

Institutional Trading of SELLAS Life Sciences Group

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE increased its position in shares of SELLAS Life Sciences Group by 21.9% during the third quarter. Bank of America Corp DE now owns 42,150 shares of the company’s stock worth $68,000 after acquiring an additional 7,571 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in SELLAS Life Sciences Group by 89.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after purchasing an additional 9,299 shares during the period. Opus Capital Group LLC boosted its stake in SELLAS Life Sciences Group by 4.2% in the 3rd quarter. Opus Capital Group LLC now owns 250,000 shares of the company’s stock worth $403,000 after purchasing an additional 10,000 shares during the period. Equitable Holdings Inc. increased its holdings in SELLAS Life Sciences Group by 58.6% during the 3rd quarter. Equitable Holdings Inc. now owns 27,060 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Axxcess Wealth Management LLC acquired a new stake in shares of SELLAS Life Sciences Group in the 3rd quarter valued at about $26,000. 17.38% of the stock is owned by institutional investors.

SELLAS Life Sciences Group Stock Performance

SLS opened at $4.35 on Friday. The company has a fifty day moving average price of $2.03 and a two-hundred day moving average price of $1.89. The firm has a market capitalization of $619.61 million, a PE ratio of -15.54 and a beta of 2.26. SELLAS Life Sciences Group has a 52 week low of $0.85 and a 52 week high of $4.66.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. Equities analysts forecast that SELLAS Life Sciences Group will post -0.57 EPS for the current year.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.